TURIN, Italy | June 19, 2026
Kither Biotech has announced the successful completion of its first-in-human Phase 1 clinical trial evaluating KIT2014, an investigational inhaled peptide therapy being developed to treat chronic obstructive pulmonary disease (COPD), non-cystic fibrosis bronchiectasis (NCFB) and cystic fibrosis (CF). The randomized, double-blind, placebo-controlled study enrolled 56 healthy participants and demonstrated that KIT2014 was safe and well tolerated across all evaluated dose levels. The positive findings mark an important milestone for the clinical-stage biotechnology company as it advances the novel therapy toward patient studies. Designed with a multimodal mechanism of action, KIT2014 aims to improve respiratory function by delivering bronchodilatory and anti-inflammatory effects directly to the lungs while minimizing systemic drug exposure, potentially offering a differentiated treatment approach for chronic respiratory diseases with significant unmet medical needs.
Phase 1 Study Demonstrates Favorable Safety and Tolerability
The Phase 1 trial evaluated single ascending doses (SAD) and multiple ascending doses (MAD) of KIT2014, with participants receiving doses ranging from 0.1 mg to 2 mg daily for up to seven days. According to the company, the investigational therapy demonstrated a favorable safety and tolerability profile, successfully meeting the study’s primary objective. Importantly, blood plasma concentrations of KIT2014 remained below the limit of detection throughout both study phases, indicating that inhalation delivers the therapy directly to the lungs with minimal systemic exposure. This localized delivery strategy may reduce the risk of systemic side effects while maximizing therapeutic activity within the respiratory tract. The study also evaluated pharmacokinetics as a secondary endpoint, providing encouraging evidence that the inhaled peptide remains largely confined to the lungs following administration.
Novel Mechanism Targets Multiple Respiratory Pathways
KIT2014 is a 42-amino acid cell-permeable peptide specifically engineered for inhalation therapy to address multiple biological pathways involved in chronic respiratory diseases. The therapy works through balanced dual inhibition of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4), increasing local concentrations of cyclic adenosine monophosphate (cAMP) within airway cells. Elevated cAMP levels are expected to promote bronchodilation, helping relax airway muscles, while simultaneously reducing lung inflammation, a key driver of disease progression in COPD, NCFB, and cystic fibrosis. By combining these complementary mechanisms within a single inhaled therapy, KIT2014 has the potential to offer broader therapeutic benefits than treatments targeting only one disease pathway, supporting improved respiratory function and symptom control.
Advertisement
Company Advances Toward Patient Studies
Following the successful completion of the first-in-human study, Kither Biotech plans to advance KIT2014 into clinical trials involving patients with COPD and other chronic respiratory disorders to further evaluate its efficacy and therapeutic potential. Company leadership highlighted the favorable safety profile and unique multimodal mechanism as important foundations for continued development. The biotechnology company has raised approximately $26 million from leading life sciences investors to support its respiratory disease pipeline and continues to focus on innovative therapies targeting significant unmet medical needs. As preparations begin for future patient studies, KIT2014 represents a promising investigational candidate that could expand treatment options for individuals living with chronic respiratory diseases by combining targeted lung delivery, minimal systemic exposure, and dual bronchodilatory and anti-inflammatory activity in a single inhaled therapy.
Source: Kither Biotech press release
